Danazol Therapy in Hypoplasminogenemia

• References

• 1 Hasegawa DK, Tyler BJ, Edson JR. Thrombotic disease in three families with inherited plasminogen deficiency. Blood 1982; 60 (Suppl 1) 213a
• 2 Shigekiyo T, Uno Y, Tomonari A, Satoh K, Hondo H, Ueda S, Saito S. Type I congenital plasminogen deficiency is not a risk factor for thrombosis. Thromb Haemostas 1992; 67: 189-192
• 3 Mannucci PM, Kluft C, Traas DW, Seveso P, D'Angelo A. Congenital plasminogen deficiency associated with venous thromboembolism: therapeutic trial with stanozolol. Br J Haematol 1986; 63: 753-759
• 4 Dolan G, Greaves M, Cooper P, Preston FE. Thrombovascular disease and familial plasminogen deficiency: a report of three kindreds. Br J Haematol 1988; 70: 417-421
• 5 Mayer K, Hartman H, Immel A, Seitz R, Egbring R. Congenital heterozygote hypoplasminogenemia as a risk factor for thrombosis. Fibrinolysis 1988; 2 (Suppl 2) 37-38
• 6 Hach-Wunderle V, Scharrer I, Lottenberg R. Congenital deficiency of plasminogen and its relationship to venous thrombosis. Thromb Haemostas 1988; 59: 277-280
• 7 Laurell CB, Rannevik G. A comparison of plasma protein changes induced by danazol, pregnancy, and estrogens. J Clin Endocrinol Metabol 1979; 49: 719-725
• 8 Lottenberg R, Dolly FR, Kitchens CS. Recurring thromboembolic disease and pulmonary hypertension associated with severe hypoplasminogenemia. Am J Hematol 1985; 19: 181-193
• 9 Kluft C, Preston FE, Malia RG, Bertina RM, Wijngaards G, Greaves M, Verheijen JH, Dooijewaard G. Stanozolol-induced changes in fibrinolysis and coagulation in healthy adults. Thromb Haemostas 1984; 51: 157-164